MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Biogen Idec Company Profile (NASDAQ:BIIB)

Consensus Ratings for Biogen Idec (NASDAQ:BIIB) (?)
Ratings Breakdown: 5 Hold Rating(s), 14 Buy Rating(s)
Consensus Rating:Buy (Score: 2.74)
Consensus Price Target: $453.50 (12.17% upside)

Current Analysts' Coverage Summary for Biogen Idec (NASDAQ:BIIB)
Show:
DateFirmActionRatingPrice TargetActions
7/2/2015Deutsche BankReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015Piper JaffrayReiterated RatingBuy$485.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2015Morgan StanleySet Price TargetBuy$520.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/11/2015Leerink SwannLower Price TargetOutperform$532.00 -> $512.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2015BMO Capital MarketsReiterated RatingOutperform$511.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015ArgusBoost Price TargetBuy$440.00 -> $450.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015NomuraReiterated RatingNeutral$401.00 -> $442.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015Citigroup Inc.Lower Price TargetBuy$512.00 -> $497.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015OppenheimerInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2015BarclaysReiterated RatingOverweight$500.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2015Stifel NicolausDowngradeBuy -> Hold$451.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2015Credit SuisseReiterated RatingOutperform$400.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2014S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/22/2014Robert W. BairdUpgradeNeutral -> Outperform$382.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/1/2014Bank of AmericaInitiated CoverageNeutral$371.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2014Jefferies GroupReiterated RatingBuy$380.00 -> $410.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/30/2014Brean CapitalBoost Price TargetBuy$293.00 -> $377.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2014Canaccord GenuityBoost Price TargetBuy$291.00 -> $355.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2013FBR & Co.UpgradeUnderperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/22/2013Wells Fargo & Co.Reiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/18/2013Goldman SachsBoost Price Target$220.00 -> $240.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2013Sanford C. BernsteinReiterated RatingMarket Perform$231.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/3/2013 forward)